Melanoma genomics – will we go beyond BRAF in clinics?
Abstract In the era of next-generation sequencing, the genetic background of cancer, including melanoma, appears to be thoroughly established. However, evaluating the oncogene BRAF mutation in codon V600 is still the only companion diagnostic genomic test commonly implemented in clinics for molecula...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2024-09-01
|
| Series: | Journal of Cancer Research and Clinical Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s00432-024-05957-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823863416901599232 |
|---|---|
| author | Justyna Mirek Wiesław Bal Magdalena Olbryt |
| author_facet | Justyna Mirek Wiesław Bal Magdalena Olbryt |
| author_sort | Justyna Mirek |
| collection | DOAJ |
| description | Abstract In the era of next-generation sequencing, the genetic background of cancer, including melanoma, appears to be thoroughly established. However, evaluating the oncogene BRAF mutation in codon V600 is still the only companion diagnostic genomic test commonly implemented in clinics for molecularly targeted treatment of advanced melanoma. Are we wasting the collected genomic data? Will we implement our current genomic knowledge of melanoma in clinics soon? This question is rather urgent because new therapeutic targets and biomarkers are needed to implement more personalized, patient-tailored therapy in clinics. Here, we provide an update on the molecular background of melanoma, including a description of four already established molecular subtypes: BRAF+, NRAS+, NF1+, and triple WT, as well as relatively new NGS-derived melanoma genes such as PREX2, ERBB4, PPP6C, FBXW7, PIK3CA, and IDH1. We also present a comparison of genomic profiles obtained in recent years with a focus on the most common melanoma genes. Finally, we propose our melanoma gene panel consisting of 22 genes that, in our opinion, are “must-have” genes in both melanoma-specific genomic tests and pan-cancer tests established to improve the treatment of melanoma further. |
| format | Article |
| id | doaj-art-3764da1d0a3d43aeaa1485217077310c |
| institution | Kabale University |
| issn | 1432-1335 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | Springer |
| record_format | Article |
| series | Journal of Cancer Research and Clinical Oncology |
| spelling | doaj-art-3764da1d0a3d43aeaa1485217077310c2025-02-09T12:10:04ZengSpringerJournal of Cancer Research and Clinical Oncology1432-13352024-09-01150911310.1007/s00432-024-05957-2Melanoma genomics – will we go beyond BRAF in clinics?Justyna Mirek0Wiesław Bal1Magdalena Olbryt2Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice BranchChemotherapy Day Unit, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice BranchCenter for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice BranchAbstract In the era of next-generation sequencing, the genetic background of cancer, including melanoma, appears to be thoroughly established. However, evaluating the oncogene BRAF mutation in codon V600 is still the only companion diagnostic genomic test commonly implemented in clinics for molecularly targeted treatment of advanced melanoma. Are we wasting the collected genomic data? Will we implement our current genomic knowledge of melanoma in clinics soon? This question is rather urgent because new therapeutic targets and biomarkers are needed to implement more personalized, patient-tailored therapy in clinics. Here, we provide an update on the molecular background of melanoma, including a description of four already established molecular subtypes: BRAF+, NRAS+, NF1+, and triple WT, as well as relatively new NGS-derived melanoma genes such as PREX2, ERBB4, PPP6C, FBXW7, PIK3CA, and IDH1. We also present a comparison of genomic profiles obtained in recent years with a focus on the most common melanoma genes. Finally, we propose our melanoma gene panel consisting of 22 genes that, in our opinion, are “must-have” genes in both melanoma-specific genomic tests and pan-cancer tests established to improve the treatment of melanoma further.https://doi.org/10.1007/s00432-024-05957-2MelanomaGenomicsNGSGenomic testingBRAF |
| spellingShingle | Justyna Mirek Wiesław Bal Magdalena Olbryt Melanoma genomics – will we go beyond BRAF in clinics? Journal of Cancer Research and Clinical Oncology Melanoma Genomics NGS Genomic testing BRAF |
| title | Melanoma genomics – will we go beyond BRAF in clinics? |
| title_full | Melanoma genomics – will we go beyond BRAF in clinics? |
| title_fullStr | Melanoma genomics – will we go beyond BRAF in clinics? |
| title_full_unstemmed | Melanoma genomics – will we go beyond BRAF in clinics? |
| title_short | Melanoma genomics – will we go beyond BRAF in clinics? |
| title_sort | melanoma genomics will we go beyond braf in clinics |
| topic | Melanoma Genomics NGS Genomic testing BRAF |
| url | https://doi.org/10.1007/s00432-024-05957-2 |
| work_keys_str_mv | AT justynamirek melanomagenomicswillwegobeyondbrafinclinics AT wiesławbal melanomagenomicswillwegobeyondbrafinclinics AT magdalenaolbryt melanomagenomicswillwegobeyondbrafinclinics |